Picture of GeneDx Holdings logo

WGS GeneDx Holdings Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Annual cashflow statement for GeneDx Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-29.7-241-245-549-176
Depreciation
Non-Cash Items5.3112325.1-24.41.05
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.73713.88.08195-39.2
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities-18.7-93.1-190-319-180
Capital Expenditures-15.5-32-20.8-14.3-5.71
Purchase of Fixed Assets
Software Development Costs
Other Investing Cash Flow Items00-127-38
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-15.5-32-20.8-141-43.7
Financing Cash Flow Items30.905061980
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities148129494197186
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash1143.95283-263-37.6